G7 Health Topics: Plenty Of Talk, Limited Action
This article was originally published in PharmAsia News
Executive Summary
Pushed in part by host Japan, health issues including antimicrobial resistance and incentives for drug R&D in this and other sectors formed an important part of the agenda at last week's G7 meeting. But while there was plenty of recognition of important issues, concrete progress was limited.
You may also be interested in...
Japan Builds Asia Links Through New AMED Programs
In line with similar initiatives by Japan on other regulatory fronts, the country's Agency for Medical Research and Development is building up its partnerships and presence in Asia.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.